Training Example: VRAYLAR (AbbVie Inc.) – Review the Data, Give Your Score & Compare to the Real AI Evaluation

[IMG: VRAYLAR® (cariprazine) logo]

[H1] Breaking through to relief is possible. Discover VRAYLAR
[H2] Proven to help control symptoms in the following conditions:

Major depressive disorder*

Bipolar I disorder*

*Approved to treat adults with major depressive disorder (along with an antidepressant), and the full spectrum of bipolar I episodes: depressive, acute manic, or mixed episodes.

[IMG: 1.4 million patients treated with VRAYLAR. Since 2015. Inclusive of all indications.]

1.5 Million Patients Treated With VRAYLAR†

†Since 2015. Inclusive of all adult indications.

See below for indications and FDA approval dates.‡

[H3] Talk to your healthcare provider about whether once-daily VRAYLAR could be right for you.

Save on VRAYLAR

Eligible commercially insured patients may pay as little as $0 for both 30- and 90-day fills of VRAYLAR.§∥

Get your savings card

Find a healthcare provider

Search for a mental health specialist in your area, using filters like distance, specialty, telehealth, and language.

Connect with a provider

Start the conversation

Answer 3 simple questions to create a personalized discussion guide for your next appointment.

Create your discussion guide

§See our Terms and Conditions to see if you qualify.
∥Eligibility: Available to patients with commercial insurance coverage for VRAYLAR® (cariprazine) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit VRAYLARsavingscard.com or call 1-844-4VRAYLAR for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy

‡VRAYLAR is approved in adults:
-along with antidepressant medicines to treat major depressive disorder (MDD; approved 2022),
-for the treatment of depressive episodes that happen with bipolar I (bipolar depression; approved 2019),
-for the acute treatment of manic or mixed episodes that happen with bipolar I disorder (approved 2015),
-for the treatment of schizophrenia (approved 2015).

INDICATIONS AND USAGE
VRAYLAR is a prescription medicine used:
along with antidepressant medicines to treat major depressive disorder (MDD) in adults
to treat depressive episodes that happen with bipolar I disorder (bipolar depression) in adults
to treat short-term (acute) manic or mixed episodes that happen with bipolar I disorder in adults and children ages 10 years and older

IMPORTANT SAFETY INFORMATION
What is the most important information I should know about VRAYLAR?
Elderly people with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) taking medicines like VRAYLAR are at an increased risk of death. VRAYLAR is not approved for treating patients with dementia-related psychosis.
VRAYLAR and antidepressants increase the risk of suicidal thoughts or actions in people 24 years of age and younger especially within the first few months of treatment or when the dose is changed. Depression and other mental illnesses are the most important causes of suicidal thoughts and actions. Patients on antidepressants and their families or caregivers should watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when VRAYLAR or the antidepressant is started or when the dose is changed. Report any change in these symptoms immediately to the doctor.
VRAYLAR may cause serious side effects, including:
Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death
Neuroleptic malignant syndrome (NMS): Call your healthcare provider or go to the nearest hospital emergency room right away if you have high fever, stiff muscles, confusion, increased sweating, or changes in breathing, heart rate, and blood pressure. These can be symptoms of a rare but potentially fatal side effect called NMS. VRAYLAR should be stopped if you have NMS.
Uncontrolled body movements (tardive dyskinesia or TD): VRAYLAR may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking VRAYLAR. Tardive dyskinesia may also start after you stop taking VRAYLAR.
Late-occurring side effects: VRAYLAR stays in your body for a long time. Some side effects may not happen right away and can start a few weeks after starting VRAYLAR, or if your dose increases. Your healthcare provider should monitor you for side effects for several weeks after starting or increasing dose of VRAYLAR.
Problems with your metabolism, such as:
High blood sugar and diabetes: Increases in blood sugar can happen in some people who take VRAYLAR. Extremely high blood sugar can lead to coma or death. Your healthcare provider should check your blood sugar before or soon after starting VRAYLAR and regularly during treatment. Tell your healthcare provider if you have symptoms such as feeling very thirsty, very hungry, or sick to your stomach, urinating more than usual, feeling weak, tired, confused, or your breath smells fruity.
Increased fat levels (cholesterol and triglycerides) in your blood: Your healthcare provider should check fat levels in your blood before or soon after starting VRAYLAR and during treatment.
Weight gain: Weight gain has been reported with VRAYLAR. You and your healthcare provider should check your weight before and regularly during treatment.
Low white blood cell count: Low white blood cell counts have been reported with antipsychotic drugs, including VRAYLAR. This may increase your risk of infection. Very low white blood cell counts, which can be fatal, have been reported with other antipsychotics. Your healthcare provider may do blood tests during the first few months of treatment with VRAYLAR.
Decreased blood pressure (orthostatic hypotension): You may feel lightheaded or faint when you rise too quickly from a sitting or lying position.
Falls: VRAYLAR may make you sleepy or dizzy, may cause a decrease in blood pressure when changing position (orthostatic hypotension), and can slow thinking and motor skills, which may lead to falls that can cause fractures or other injuries.
Seizures (convulsions)
Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities: Do NOT drive, operate machinery, or do other dangerous activities until you know how VRAYLAR affects you. VRAYLAR may make you drowsy.
Increased body temperature: Do not become too hot or dehydrated during VRAYLAR treatment. Do not exercise too much. In hot weather, stay inside in a cool place if possible. Stay out of the sun. Do not wear too much clothing or heavy clothing. Drink plenty of water.
Difficulty swallowing that can cause food or liquid to get into your lungs
Who should not take VRAYLAR?
Do not take VRAYLAR if you are allergic to any of its ingredients. Get emergency medical help if you are having an allergic reaction (eg, rash, itching, hives, swelling of the tongue, lip, face or throat).
What should I tell my healthcare provider before taking VRAYLAR?
Tell your healthcare provider about any medical conditions and if you:
have or had heart problems or a stroke
have or had low or high blood pressure
have or had diabetes or high blood sugar in you or your family
have or had high levels of total cholesterol, LDL-cholesterol, or triglycerides; or low levels of HDL-cholesterol
have or had seizures (convulsions)
have or had kidney or liver problems
have or had low white blood cell count
are pregnant or plan to become pregnant. VRAYLAR may harm your unborn baby. Taking VRAYLAR during your third trimester of pregnancy may cause your baby to have abnormal muscle movements or withdrawal symptoms after birth. Talk to your healthcare provider about the risk to your unborn baby if you take VRAYLAR during pregnancy. There is a pregnancy exposure registry for women who are exposed to VRAYLAR during pregnancy. If you become pregnant or think you are pregnant during treatment, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or http://www.womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.
are breastfeeding or plan to breastfeed. It is not known if VRAYLAR passes into breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with VRAYLAR.
Tell your healthcare provider about all medicines that you take, including prescriptions, over-the-counter medicines, vitamins, and supplements. VRAYLAR may affect the way other medicines work, and other medicines may affect how VRAYLAR works. Do not start or stop any medicines while taking VRAYLAR without talking to your healthcare provider.
What are the most common side effects of VRAYLAR?
The most common side effects include difficulty moving or slow movements, tremors, uncontrolled body movements, restlessness and feeling like you need to move around, sleepiness, nausea, vomiting, indigestion, constipation, feeling tired, trouble sleeping, increased appetite, and dizziness.
These are not all the possible side effects of VRAYLAR.
VRAYLAR is available in 0.5 mg, 0.75 mg, 1.5 mg, 3 mg, 4.5 mg, and 6 mg capsules.
INDICATIONS AND USAGE
VRAYLAR is a prescription medicine used:
along with antidepressant medicines to treat major depressive disorder (MDD) in adults
to treat depressive episodes that happen with bipolar I disorder (bipolar depression) in adults
to treat short-term (acute) manic or mixed episodes that happen with bipolar I disorder in adults and children ages 10 years and older
Please see the full Prescribing Information, including Boxed Warnings, and Medication Guide.
US-VRAA-250457

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

[H2] You are now leaving VRAYLAR.com
You are leaving the VRAYLAR (cariprazine) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of VRAYLAR.com or AbbVie.
Do you wish to leave this site?

YES

NO

US-VRA-230180

You are now leaving VRAYLAR.com

Links to other websites are provided as a service to you. AbbVie accepts no responsibility for the content of other sites.
Would you like to continue?

YES

NO

US-VRAA-220054

[H2] For Healthcare Professionals
The information provided in this website is intended for U.S. healthcare professionals only.
I certify that I am a U.S. healthcare professional.
If you choose “NO,” you will remain on the patient website.

YES

NO

US-VRA-230180

[H3] You are now leaving VRAYLAR.com

You are leaving the VRAYLAR (cariprazine) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of VRAYLAR.com or AbbVie.
Do you wish to leave this site?

Yes

No

US-VRA-230180

[H2] For residents of Puerto Rico
By selecting ‘continue’ you will enter the VRAYLAR Puerto Rico website, which includes key information presented in Spanish. Cost & Savings information on this site is intended for Puerto Rico residents only.
If you are a U.S. resident looking for cost information, please select ‘Back’ and visit the Cost & Savings page.

Continue

Back

US-VRAA-240126
US-VRA-240106

[H3] INDICATIONS AND USAGE
VRAYLAR is a prescription medicine used:
along with antidepressant medicines to treat major depressive disorder (MDD) in adults
to treat depressive episodes that happen with bipolar I disorder (bipolar depression) in adults
to treat short-term (acute) manic or mixed episodes that happen with bipolar I disorder in adults and children ages 10 years and older

[H3] IMPORTANT SAFETY INFORMATION
What is the most important information I should know about VRAYLAR?
Elderly people with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) taking medicines like VRAYLAR are at an increased risk of death. VRAYLAR is not approved for treating patients with dementia-related psychosis.
VRAYLAR and antidepressants increase the risk of suicidal thoughts or actions in people 24 years of age and younger especially within the first few months of treatment or when the dose is

[H3] IMPORTANT SAFETY INFORMATION
Elderly people with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) taking medicines like VRAYLAR are at an increased risk of

Feeling stuck in your head with unresolved symptoms of major depressive disorder? Ask about adding VRAYLAR to your antidepressant.
[H1] Help break through to relief

See what VRAYLAR can do

Struggling with unresolved symptoms of major depressive disorder?
Ask about adding VRAYLAR to your antidepressant.

See what VRAYLAR can do

[H3] Why consider an add-on treatment?

Discover more options

[H3] How can I find a healthcare provider near me?

Find a provider

[IMG: Question mark icon.]

[H2] Why consider an add-on treatment?

Discover more options

[IMG: Healthcare provider icon.]

[H2] How can I find a healthcare provider near me?

Find a provider

[IMG: 1.4 million patients treated with VRAYLAR. Since 2015. Inclusive of all indications.]

[H2] Have you ever tried an add-on treatment, along with your antidepressant?

Select an answer below to discover options that may be right for you.

Yes, but I'd like to learn more about VRAYLAR
No, but I'm interested in seeing how VRAYLAR may help
No, but I would like to learn more about managing depression

Yes, but I'd like to learn more about VRAYLAR
How could VRAYLAR help me?
Adding VRAYLAR to an antidepressant is clinically proven to help relieve overall depression symptoms better than an antidepressant alone.‡
See what VRAYLAR can do
‡Individual results may vary.

No, but I’m interested in seeing how VRAYLAR may help
How can I start the conversation about VRAYLAR?
Answer 3 simple questions to create a personalized discussion guide for your next appointment with your healthcare team.
Start now

No, but I would like to learn more about managing depression
How can I manage my depressive symptoms?
Get a refresher on ways to manage depression and how add-on treatments may be able to help.
Get insights

Reset

[H2] Hear about Kami's experience with adding VRAYLAR

Meet Kami, a real patient with MDD who is taking VRAYLAR with her antidepressant to help manage her depression symptoms.

Watch Kami’s story

The person featured in this video is sharing her individual experience with VRAYLAR. Individual experiences with the condition and treatment will vary. Talk to your healthcare provider to see if VRAYLAR may be right for you.

Watch Kami’s story

[H2] Make the most out of your appointment
Help your provider understand how you’re feeling. Complete this simple quiz about your symptoms to create a personalized discussion guide for your next appointment.

Take quiz

*Terms and conditions apply. Available to commercially insured patients only. See Terms and Conditions for full details.

INDICATION AND USAGE
VRAYLAR is a prescription medicine used along with antidepressant medicines to treat major depressive disorder (MDD) in adults.

IMPORTANT SAFETY INFORMATION
What is the most important information I should know about VRAYLAR?
Elderly people with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) taking medicines like VRAYLAR are at an increased risk of death. VRAYLAR is not approved for treating patients with dementia-related psychosis.
VRAYLAR and antidepressants increase the risk of suicidal thoughts or actions in people 24 years of age and younger especially within the first few months of treatment or when the dose is changed. Depression and other mental illnesses are the most important causes of suicidal thoughts and actions. Patients on antidepressants and their families or caregivers should watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when VRAYLAR or the antidepressant is started or when the dose is changed. Report any change in these symptoms immediately to the doctor.
VRAYLAR may cause serious side effects, including:
Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death
Neuroleptic malignant syndrome (NMS): Call your healthcare provider or go to the nearest hospital emergency room right away if you have high fever, stiff muscles, confusion, increased sweating, or changes in breathing, heart rate, and blood pressure. These can be symptoms of a rare but potentially fatal side effect called NMS. VRAYLAR should be stopped if you have NMS.
Uncontrolled body movements (tardive dyskinesia or TD): VRAYLAR may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking VRAYLAR. Tardive dyskinesia may also start after you stop taking VRAYLAR.
Late-occurring side effects: VRAYLAR stays in your body for a long time. Some side effects may not happen right away and can start a few weeks after starting VRAYLAR, or if your dose increases. Your healthcare provider should monitor you for side effects for several weeks after starting or increasing dose of VRAYLAR.
Problems with your metabolism, such as:
High blood sugar and diabetes: Increases in blood sugar can happen in some people who take VRAYLAR. Extremely high blood sugar can lead to coma or death. Your healthcare provider should check your blood sugar before or soon after starting VRAYLAR and regularly during treatment. Tell your healthcare provider if you have symptoms such as feeling very thirsty, very hungry, or sick to your stomach, urinating more than usual, feeling weak, tired, confused, or your breath smells fruity.
Increased fat levels (cholesterol and triglycerides) in your blood: Your healthcare provider should check fat levels in your blood before or soon after starting VRAYLAR and during treatment.
Weight gain: Weight gain has been reported with VRAYLAR. You and your healthcare provider should check your weight before and regularly during treatment.
Low white blood cell count: Low white blood cell counts have been reported with antipsychotic drugs, including VRAYLAR. This may increase your risk of infection. Very low white blood cell counts, which can be fatal, have been reported with other antipsychotics. Your healthcare provider may do blood tests during the first few months of treatment with VRAYLAR.
Decreased blood pressure (orthostatic hypotension): You may feel lightheaded or faint when you rise too quickly from a sitting or lying position.
Falls: VRAYLAR may make you sleepy or dizzy, may cause a decrease in blood pressure when changing position (orthostatic hypotension), and can slow thinking and motor skills, which may lead to falls that can cause fractures or other injuries.
Seizures (convulsions)
Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities: Do NOT drive, operate machinery, or do other dangerous activities until you know how VRAYLAR affects you. VRAYLAR may make you drowsy.
Increased body temperature: Do not become too hot or dehydrated during VRAYLAR treatment. Do not exercise too much. In hot weather, stay inside in a cool place if possible. Stay out of the sun. Do not wear too much clothing or heavy clothing. Drink plenty of water.
Difficulty swallowing that can cause food or liquid to get into your lungs
Who should not take VRAYLAR?
Do not take VRAYLAR if you are allergic to any of its ingredients. Get emergency medical help if you are having an allergic reaction (eg, rash, itching, hives, swelling of the tongue, lip, face or throat).
What should I tell my healthcare provider before taking VRAYLAR?
Tell your healthcare provider about any medical conditions and if you:
have or had heart problems or a stroke
have or had low or high blood pressure
have or had diabetes or high blood sugar in you or your family
have or had high levels of total cholesterol, LDL-cholesterol, or triglycerides; or low levels of HDL-cholesterol
have or had seizures (convulsions)
have or had kidney or liver problems
have or had low white blood cell count
are pregnant or plan to become pregnant. VRAYLAR may harm your unborn baby. Taking VRAYLAR during your third trimester of pregnancy may cause your baby to have abnormal muscle movements or withdrawal symptoms after birth. Talk to your healthcare provider about the risk to your unborn baby if you take VRAYLAR during pregnancy. There is a pregnancy exposure registry for women who are exposed to VRAYLAR during pregnancy. If you become pregnant or think you are pregnant during treatment, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or http://www.womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.
are breastfeeding or plan to breastfeed. It is not known if VRAYLAR passes into breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with VRAYLAR.
Tell your healthcare provider about all medicines that you take, including prescriptions, over-the-counter medicines, vitamins, and supplements. VRAYLAR may affect the way other medicines work, and other medicines may affect how VRAYLAR works. Do not start or stop any medicines while taking VRAYLAR without talking to your healthcare provider.
What are the most common side effects of VRAYLAR?
The most common side effects include difficulty moving or slow movements, tremors, uncontrolled body movements, restlessness and feeling like you need to move around, sleepiness, nausea, vomiting, indigestion, constipation, feeling tired, trouble sleeping, increased appetite, and dizziness.
These are not all the possible side effects of VRAYLAR.
VRAYLAR is available in 0.5 mg, 0.75 mg, 1.5 mg, 3 mg, 4.5 mg, and 6 mg capsules.
INDICATIONS AND USAGE
VRAYLAR is a prescription medicine used:
along with antidepressant medicines to treat major depressive disorder (MDD) in adults
to treat depressive episodes that happen with bipolar I disorder (bipolar depression) in adults
to treat short-term (acute) manic or mixed episodes that happen with bipolar I disorder in adults and children ages 10 years and older
Please see the full Prescribing Information, including Boxed Warnings, and Medication Guide.
US-VRAA-250457

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

You are now leaving VRAYLAR.com

You are leaving the VRAYLAR (cariprazine) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of VRAYLAR.com or AbbVie.
Do you wish to leave this site?

YES

NO

US-VRAA-230191

[H3] You are now leaving VRAYLAR.com
Links to other websites are provided as a service to you.
AbbVie accepts no responsibility for the content of other sites.
Would you like to continue?

YES

NO

US-VRAA-220054

[H3] You are now leaving VRAYLAR.com
Links to other websites are provided as a service to you.
AbbVie accepts no responsibility for the content of other sites.
Would you like to continue?

YES

NO

US-VRAA-220054

For Healthcare Professionals

The information provided in this website is intended for U.S. healthcare professionals only.
I certify that I am a U.S. healthcare professional.
If you choose “NO,” you will remain on the patient website.

YES

NO

US-VRAA-220054

[H2] You are now leaving VRAYLAR.com
You are leaving the VRAYLAR (cariprazine) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site, and AbbVie makes no guarantee that any such support groups will result in your desired outcome. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of VRAYLAR.com or AbbVie.
Do you wish to leave this site?

YES

NO

US-VRA-230116test

[H2] You are now leaving VRAYLAR.com
You are leaving the VRAYLAR (cariprazine) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of VRAYLAR.com or AbbVie.
Do you wish to leave this site?

YES

NO

US-VRA-230180

You are now leaving VRAYLAR.com

Links to other websites are provided as a service to you. AbbVie accepts no responsibility for the content of other sites.
Would you like to continue?

YE

[H1] Help break through the highs and lows of bipolar I

Help take control of your bipolar I symptoms and ask about VRAYLAR.

Learn about VRAYLAR

[IMG: Question mark icon.]

[H2] Could it be bipolar I?

Take quiz

[IMG: Healthcare provider icon.]

[H2] Already taking VRAYLAR?

Get support now

[H2] Find a healthcare provider near you

Search for a mental health provider in your area who may help you manage your bipolar I‡

‡By clicking through to search for healthcare providers, you acknowledge and agree with the Terms and Conditions.

PLEASE NOTE: While we update our directory regularly, this list may not have current provider information. This is an AbbVie Inc.-compiled list of prescribers known to have prescribed therapies including VRAYLAR in the past 12 months. The results shown may not be inclusive of all providers who may have experience with therapies such as VRAYLAR in your area. Please see the Terms and Conditions for additional details.

[IMG: Patient on a virtual appointment with their healthcare provider.]

‡By clicking through to search for healthcare providers, you acknowledge and agree with the Terms and Conditions.
PLEASE NOTE: While we update our directory regularly, this list may not have current provider information. This is an AbbVie Inc.-compiled list of prescribers known to have prescribed therapies including VRAYLAR in the past 12 months. The results shown may not be inclusive of all providers who may have experience with therapies such as VRAYLAR in your area. Please see the Terms and Conditions for additional details.

[H2] Have you taken any medication(s) for your bipolar I?

Select an answer below to learn how VRAYLAR may work to treat your bipolar I.

Yes, I have taken multiple medications to help treat my bipolar I.
Yes, I have taken one medication to treat my bipolar I.
No, but I would like to learn more about managing bipolar I.

Yes, I have taken multiple medications to help treat my bipolar I.
Can VRAYLAR treat the highs AND lows?
There are many ways to manage your bipolar I. Learn how VRAYLAR can help treat depressive, acute manic and acute mixed episodes of bipolar I.
Get to know VRAYLAR

Yes, I have taken one medication to treat my bipolar I.
How can I treat the highs AND lows?
You may experience bipolar I depressive, acute mixed and acute manic episodes. It is important to treat all parts of bipolar I. Learn how VRAYLAR can help by treating both the highs and lows.
See VRAYLAR in action

No, but I would like to learn more about managing bipolar I.
How can I learn more about managing the highs and lows?
Learn more about treating the highs and lows and hear real stories from people living with bipolar I.
Get more information

Reset

[IMG: Speech bubbles icon.]

[H2] Make the most out of your appointment
Help your provider understand how you’re feeling. Complete this simple quiz about your symptoms to create a personalized discussion guide for your next appointment.

Take quiz

[H2] Real people, real stories
Discover the real stories of real people living with bipolar I disorder.
The people featured in these videos are sharing their individual experiences of living with bipolar I disorder. Individual experiences with the condition and treatment will vary. Not all of those featured are currently taking VRAYLAR. These videos are brought to you by AbbVie.
[H3] Talk to your healthcare provider to see if VRAYLAR may be right for you.
A real VRAYLAR story featuring: Alec and his toolbox

Watch Now

View transcript
A real VRAYLAR story featuring: Alec and his toolbox
In this real VRAYLAR story, Alec shares his treatment journey and the tools that help him manage his bipolar I.

See more stories

Watch Now

Heidi shares how bipolar I is part of who she is

Watch Now

Dailyn, a spoken word poet, addresses stigma

Watch Now

Jon’s journey through misdiagnosis

Watch Now

Alec’s family helps him manage bipolar I

See more stories

[H2] Having trouble remembering
your highs and lows?
Use this mood tracker to record your symptoms each day, which may help your healthcare provider spot warning signs of bipolar I disorder.

Track my mood

[H2] Breaking through to relief is possible
Watch our TV ad and ask your doctor if VRAYLAR may be able to help you break through the highs and lows.

[IMG: TV ad video thumbnail]

Watch Now

View Transcript

[H2] Additional resources

[IMG: Envelope icon.]

[H3] Bipolar I support
Sign up for wellness support sent directly to your inbox.

Get updates

[IMG: question mark]

[H3] Could it be bipolar I?
Answer some questions that could help your healthcare provider determine whether you may have bipolar I disorder.

Take the quiz

[IMG: Savings card icon.]

[H3] Save on VRAYLAR
Eligible patients may pay as little as $0 for their 30- or 90-day fills of VRAYLAR.*§

Get your coupon

*Terms and conditions apply. Available to commercially insured patients only. See Terms and Conditions for full details.

§Eligibility: Available to patients with commercial insurance coverage for VRAYLAR® (cariprazine) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit VRAYLARsavingscard.com or call 1-844-4VRAYLAR1-844-4VRAYLAR for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.

INDICATIONS AND USAGE
VRAYLAR is a prescription medicine used to treat depressive episodes that happen with bipolar I disorder (bipolar depression) in adults and to treat short-term (acute) manic or mixed episodes that happen with bipolar I disorder in adults and children ages 10 years and older.

IMPORTANT SAFETY INFORMATION
What is the most important information I should know about VRAYLAR?
Elderly people with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) taking medicines like VRAYLAR are at an increased risk of death. VRAYLAR is not approved for treating patients with dementia-related psychosis.
VRAYLAR and antidepressants increase the risk of suicidal thoughts or actions in people 24 years of age and younger especially within the first few months of treatment or when the dose is changed. Depression and other mental illnesses are the most important causes of suicidal thoughts and actions. Patients on antidepressants and their families or caregivers should watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when VRAYLAR or the antidepressant is started or when the dose is changed. Report any change in these symptoms immediately to the doctor.
VRAYLAR may cause serious side effects, including:
Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death
Neuroleptic malignant syndrome (NMS): Call your healthcare provider or go to the nearest hospital emergency room right away if you have high fever, stiff muscles, confusion, increased sweating, or changes in breathing, heart rate, and blood pressure. These can be symptoms of a rare but potentially fatal side effect called NMS. VRAYLAR should be stopped if you have NMS.
Uncontrolled body movements (tardive dyskinesia or TD): VRAYLAR may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking VRAYLAR. Tardive dyskinesia may also start after you stop taking VRAYLAR.
Late-occurring side effects: VRAYLAR stays in your body for a long time. Some side effects may not happen right away and can start a few weeks after starting VRAYLAR, or if your dose increases. Your healthcare provider should monitor you for side effects for several weeks after starting or increasing dose of VRAYLAR.
Problems with your metabolism, such as:
High blood sugar and diabetes: Increases in blood sugar can happen in some people who take VRAYLAR. Extremely high blood sugar can lead to coma or death. Your healthcare provider should check your blood sugar before or soon after starting VRAYLAR and regularly during treatment. Tell your healthcare provider if you have symptoms such as feeling very thirsty, very hungry, or sick to your stomach, urinating more than usual, feeling weak, tired, confused, or your breath smells fruity.
Increased fat levels (cholesterol and triglycerides) in your blood: Your healthcare provider should check fat levels in your blood before or soon after starting VRAYLAR and during treatment.
Weight gain: Weight gain has been reported with VRAYLAR. You and your healthcare provider should check your weight before and regularly during treatment.
Low white blood cell count: Low white blood cell counts have been reported with antipsychotic drugs, including VRAYLAR. This may increase your risk of infection. Very low white blood cell counts, which can be fatal, have been reported with other antipsychotics. Your healthcare provider may do blood tests during the first few months of treatment with VRAYLAR.
Decreased blood pressure (orthostatic hypotension): You may feel lightheaded or faint when you rise too quickly from a sitting or lying position.
Falls: VRAYLAR may make you sleepy or dizzy, may cause a decrease in blood pressure when changing position (orthostatic hypotension), and can slow thinking and motor skills, which may lead to falls that can cause fractures or other injuries.
Seizures (convulsions)
Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities: Do NOT drive, operate machinery, or do other dangerous activities until you know how VRAYLAR affects you. VRAYLAR may make you drowsy.
Increased body temperature: Do not become too hot or dehydrated during VRAYLAR treatment. Do not exercise too much. In hot weather, stay inside in a cool place if possible. Stay out of the sun. Do not wear too much clothing or heavy clothing. Drink plenty of water.
Difficulty swallowing that can cause food or liquid to get into your lungs
Who should not take VRAYLAR?
Do not take VRAYLAR if you are allergic to any of its ingredients. Get emergency medical help if you are having an allergic reaction (eg, rash, itching, hives, swelling of the tongue, lip, face or throat).
What should I tell my healthcare provider before taking VRAYLAR?
Tell your healthcare provider about any medical conditions and if you:
have or had heart problems or a stroke
have or had low or high blood pressure
have or had diabetes or high blood sugar in you or your family
have or had high levels of total cholesterol, LDL-cholesterol, or triglycerides; or low levels of HDL-cholesterol
have or had seizures (convulsions)
have or had kidney or liver problems
have or had low white blood cell count
are pregnant or plan to become pregnant. VRAYLAR may harm your unborn baby. Taking VRAYLAR during your third trimester of pregnancy may cause your baby to have abnormal muscle movements or withdrawal symptoms after birth. Talk to your healthcare provider about the risk to your unborn baby if you take VRAYLAR during pregnancy. There is a pregnancy exposure registry for women who are exposed to VRAYLAR during pregnancy. If you become pregnant or think you are pregnant during treatment, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or http://www.womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.
are breastfeeding or plan to breastfeed. It is not known if VRAYLAR passes into breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with VRAYLAR.
Tell your healthcare provider about all medicines that you take, including prescriptions, over-the-counter medicines, vitamins, and supplements. VRAYLAR may affect the way other medicines work, and other medicines may affect how VRAYLAR works. Do not start or stop any medicines while taking VRAYLAR without talking to your healthcare provider.
What are the most common side effects of VRAYLAR?
The most common side effects include difficulty moving or slow movements, tremors, uncontrolled body movements, restlessness and feeling like you need to move around, sleepiness, nausea, vomiting, indigestion, constipation, feeling tired, trouble sleeping, increased appetite, and dizziness.
These are not all the possible side effects of VRAYLAR.
VRAYLAR is available in 0.5 mg, 0.75 mg, 1.5 mg, 3 mg, 4.5 mg, and 6 mg capsules.
INDICATIONS AND USAGE
VRAYLAR is a prescription medicine used:
along with antidepressant medicines to treat major depressive disorder (MDD) in adults
to treat depressive episodes that happen with bipolar I disorder (bipolar depression) in adults
to treat short-term (acute) manic or mixed episodes that happen with bipolar I disorder in adults and children ages 10 years and older
Please see the full Prescribing Information, including Boxed Warnings, and Medication Guide.
US-VRAA-250457

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

[H3] Alec's bipolar I toolbox (part 1)

[H3]

Transcript

View transcript

[H1] Sign up for the VRAYLAR® Savings Program

*Eligibility: Available to patients with commercial insurance coverage for VRAYLAR® (cariprazine) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit VRAYLARsavingscard.com or call 1-844-4VRAYLAR for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy

INDICATIONS AND USAGE
VRAYLAR is a prescription medicine used:
along with antidepressant medicines to treat major depressive disorder (MDD) in adults
to treat depressive episodes that happen with bipolar I disorder (bipolar depression) in adults
to treat short-term (acute) manic or mixed episodes that happen with bipolar I disorder in adults and children ages 10 years and older

IMPORTANT SAFETY INFORMATION
What is the most important information I should know about VRAYLAR?
Elderly people with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) taking medicines like VRAYLAR are at an increased risk of death. VRAYLAR is not approved for treating patients with dementia-related psychosis.
VRAYLAR and antidepressants increase the risk of suicidal thoughts or actions in people 24 years of age and younger especially within the first few months of treatment or when the dose is changed. Depression and other mental illnesses are the most important causes of suicidal thoughts and actions. Patients on antidepressants and their families or caregivers should watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when VRAYLAR or the antidepressant is started or when the dose is changed. Report any change in these symptoms immediately to the doctor.
VRAYLAR may cause serious side effects, including:
Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death
Neuroleptic malignant syndrome (NMS): Call your healthcare provider or go to the nearest hospital emergency room right away if you have high fever, stiff muscles, confusion, increased sweating, or changes in breathing, heart rate, and blood pressure. These can be symptoms of a rare but potentially fatal side effect called NMS. VRAYLAR should be stopped if you have NMS.
Uncontrolled body movements (tardive dyskinesia or TD): VRAYLAR may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking VRAYLAR. Tardive dyskinesia may also start after you stop taking VRAYLAR.
Late-occurring side effects: VRAYLAR stays in your body for a long time. Some side effects may not happen right away and can start a few weeks after starting VRAYLAR, or if your dose increases. Your healthcare provider should monitor you for side effects for several weeks after starting or increasing dose of VRAYLAR.
Problems with your metabolism, such as:
High blood sugar and diabetes: Increases in blood sugar can happen in some people who take VRAYLAR. Extremely high blood sugar can lead to coma or death. Your healthcare provider should check your blood sugar before or soon after starting VRAYLAR and regularly during treatment. Tell your healthcare provider if you have symptoms such as feeling very thirsty, very hungry, or sick to your stomach, urinating more than usual, feeling weak, tired, confused, or your breath smells fruity.
Increased fat levels (cholesterol and triglycerides) in your blood: Your healthcare provider should check fat levels in your blood before or soon after starting VRAYLAR and during treatment.
Weight gain: Weight gain has been reported with VRAYLAR. You and your healthcare provider should check your weight before and regularly during treatment.
Low white blood cell count: Low white blood cell counts have been reported with antipsychotic drugs, including VRAYLAR. This may increase your risk of infection. Very low white blood cell counts, which can be fatal, have been reported with other antipsychotics. Your healthcare provider may do blood tests during the first few months of treatment with VRAYLAR.
Decreased blood pressure (orthostatic hypotension): You may feel lightheaded or faint when you rise too quickly from a sitting or lying position.
Falls: VRAYLAR may make you sleepy or dizzy, may cause a decrease in blood pressure when changing position (orthostatic hypotension), and can slow thinking and motor skills, which may lead to falls that can cause fractures or other injuries.
Seizures (convulsions)
Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities: Do NOT drive, operate machinery, or do other dangerous activities until you know how VRAYLAR affects you. VRAYLAR may make you drowsy.
Increased body temperature: Do not become too hot or dehydrated during VRAYLAR treatment. Do not exercise too much. In hot weather, stay inside in a cool place if possible. Stay out of the sun. Do not wear too much clothing or heavy clothing. Drink plenty of water.
Difficulty swallowing that can cause food or liquid to get into your lungs
Who should not take VRAYLAR?
Do not take VRAYLAR if you are allergic to any of its ingredients. Get emergency medical help if you are having an allergic reaction (eg, rash, itching, hives, swelling of the tongue, lip, face or throat).
What should I tell my healthcare provider before taking VRAYLAR?
Tell your healthcare provider about any medical conditions and if you:
have or had heart problems or a stroke
have or had low or high blood pressure
have or had diabetes or high blood sugar in you or your family
have or had high levels of total cholesterol, LDL-cholesterol, or triglycerides; or low levels of HDL-cholesterol
have or had seizures (convulsions)
have or had kidney or liver problems
have or had low white blood cell count
are pregnant or plan to become pregnant. VRAYLAR may harm your unborn baby. Taking VRAYLAR during your third trimester of pregnancy may cause your baby to have abnormal muscle movements or withdrawal symptoms after birth. Talk to your healthcare provider about the risk to your unborn baby if you take VRAYLAR during pregnancy. There is a pregnancy exposure registry for women who are exposed to VRAYLAR during pregnancy. If you become pregnant or think you are pregnant during treatment, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or http://www.womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.
are breastfeeding or plan to breastfeed. It is not known if VRAYLAR passes into breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with VRAYLAR.
Tell your healthcare provider about all medicines that you take, including prescriptions, over-the-counter medicines, vitamins, and supplements. VRAYLAR may affect the way other medicines work, and other medicines may affect how VRAYLAR works. Do not start or stop any medicines while taking VRAYLAR without talking to your healthcare provider.
What are the most common side effects of VRAYLAR?
The most common side effects include difficulty moving or slow movements, tremors, uncontrolled body movements, restlessness and feeling like you need to move around, sleepiness, nausea, vomiting, indigestion, constipation, feeling tired, trouble sleeping, increased appetite, and dizziness.
These are not all the possible side effects of VRAYLAR.
VRAYLAR is available in 0.5 mg, 0.75 mg, 1.5 mg, 3 mg, 4.5 mg, and 6 mg capsules.
INDICATIONS AND USAGE
VRAYLAR is a prescription medicine used:
along with antidepressant medicines to treat major depressive disorder (MDD) in adults
to treat depressive episodes that happen with bipolar I disorder (bipolar depression) in adults
to treat short-term (acute) manic or mixed episodes that happen with bipolar I disorder in adults and children ages 10 years and older
Please see the full Prescribing Information, including Boxed Warnings, and Medication Guide.
US-VRAA-250457

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

[H5] Program Terms, Conditions, and Eligibility Criteria
This offer is valid only for patients with a valid prescription for VRAYLAR® (cariprazine) capsules at the time the prescription is filled by the pharmacist and dispensed to the patient.
This offer is not valid for use by patients enrolled in Medicare, Medicaid, or other federal or state programs (including any state pharmaceutical assistance programs), or private indemnity or HMO insurance plans that reimburse you for the entire cost of your prescription drugs. If at any time a participating patient begins receiving prescription drug coverage under any federal, state, or government-funded healthcare program, the patient will no longer be eligible for this offer and must cease participation. This offer is not valid for cash-paying patients.
Eligible, commercially insured patients whose plan covers VRAYLAR® may pay as little as $0 per prescription fill of VRAYLAR®. Patient out-of-pocket expense will vary based on the patient’s insurance plan and coverage details; check with your pharmacist for your out-of-pocket discount. Restrictions, including monthly, quarterly, and/or annual maximums, may apply to ensure that this offer is being utilized solely for the patient’s benefit. Eligible patients whose insurer does not cover VRAYLAR® may pay as little as $40 for up to two 30-day fills, for an FDA approved indication, per lifetime. Eligible patients whose coverage restrictions have not been met may pay as little as $40 for up to two 30-day prescription fills, for an FDA approved indication, per lifetime.
Subject to all other terms and conditions, a commercially insured patient whose plan covers VRAYLAR® may receive up to a maximum annual benefit of $10,000 per calendar year under this offer, solely for the patient’s benefit.
Eligible, commercially insured patients who are taking VRAYLAR® as an adjunctive or add-on treatment for Major Depressive Disorder may pay as little as $0 per prescription fill of a generic antidepressant.
Patients may not seek reimbursement for value received from this program from any third-party payers.
AbbVie reserves the right to rescind, revoke, or amend this offer without notice.
Offer good only in the USA, including Puerto Rico, at participating retail pharmacies. Patients residing in or receiving treatment in certain states may not be eligible to participate in this program.
Void if prohibited by law, taxed, or restricted.
This card is not transferable. The selling, purchasing, trading, or counterfeiting of this card is prohibited by law.
This card has no cash value and may not be used in combination with any other discount, coupon, rebate, free trial, or similar offer for the specified prescription.
This offer is not health insurance.
By redeeming this offer, you acknowledge that you are an eligible, commercially insured patient and that you understand and agree to comply with the above terms and conditions.
To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.
For questions about the program, including savings on mail-order prescriptions, please call 1-844-4VRAYLAR.

US-VRAA-250493

[H2] For Healthcare Professionals
The information provided in this website is intended for U.S. healthcare professionals only.
I certify that I am a U.S. healthcare professional.
If you choose “NO,” you will remain on the patient website.

YES

NO

US-VRA-230180

[H2] You are now leaving VRAYLAR.com
You are leaving the VRAYLAR (cariprazine) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of VRAYLAR.com or AbbVie.
Do you wish to leave this site?

YES

NO

US-VRA-230180

You are now leaving VRAYLAR.com

Links to other websites are provided as a service to you. AbbVie accepts no responsibility for the content of other sites.
Would you like to continue?

YES

NO

US-VRAA-220054

[H2] For Healthcare Professionals
The information provided in this website is intended for U.S. healthcare professionals only.
I certify that I am a U.S. healthcare professional.
If you choose “NO,” you will remain on the patient website.

YES

NO

US-VRA-230180

[H3] You are now leaving VRAYLAR.com

You are leaving the VRAYLAR (cariprazine) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of VRAYLAR.com or AbbVie.
Do you wish to leave this site?

Yes

No

US-VRA-230180

[H2] For residents of Puerto Rico
By selecting ‘continue’ you will enter the VRAYLAR Puerto Rico websi